Retrotope is developing a new class of drugs designed to combat the disease and cellular degeneration that results from lipid peroxidation (LPO). By leveraging our unique insight into LPO and our proprietary technology platform, we have created a pipeline of first-in-class therapeutic candidates for the treatment of a range of devastating degenerative diseases.
Our lead drug candidate, RT001, is currently in late-stage clinical trials for the treatment of several orphan neurodegenerative diseases with few or no treatment options. This include amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), Friedreich’s ataxia (FA) and infantile neuroaxonal dystrophy (INAD).
Retrotope is growing! We need talented and curious team members who want to make an impact on the future of science and therapeutics. To make this possible, Retrotope provides a vibrant and dynamic work environment in an exciting and meaningful industry.
4300 EL CAMINO REAL,
SUITE 201, LOS ALTOS,